Code Pharma is Initiating a Phase 2 Controlled Study | Global Trend Monitor

Zyon Ayni - Global Trend Monitor

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Zyon Ayni, Founder and CEO of Code Pharma, talked to Global Trend Monitor about the phase 1 study of Codivir, a medication that battles COVID-19: “The trial was conducted at Casa de Saúde, Vera Cruz Hospital in São Paulo, Brazil, with Dr Florentino Cardoso and results showed that Codivir has a high safety profile while significantly suppressing viral patients with an antiviral effect noted as early as three days”.

Ayni added: “We are now initiating a phase 2 controlled study to be conducted in Spain, Brazil, South Africa, and Israel, with a larger cohort. Code Pharma has also submitted emergency approval requests to several affected countries and to meet the expected demand, the company is preparing for mass production of Codivir in different sites worldwide. This will be initiated end of October with larger clinical studies of a minimum of 150 people”.

More To Explore

Zyon Ayni - ynet
Press

Zyon Ayni’s Code Pharma on ynet TV

Codivir, an antiviral medication against COVID-19, was developed by Code Pharma and its Founder and CEO, Zyon Ayni. Dr. Einat Finkelstein, Chief Scientist of the company,